pacritinib (Vonjo) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

  • Now
Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis. It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).   Wikipedia

  • SMILES: C(CN1CCCC1)Oc2ccc3Nc4nccc(n4)c5cccc(COC\C=C\COCc2c3)c5
  • Mol. Mass: 472.59
  • ALogP: 4.96
  • ChEMBL Molecule:
More Chemistry
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene | onx-0803 | otl38 | pacritinib | sb1518 | sb 1518 | sb-1518


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue